England
Market Access/ Views & Analysis/ Views and analysis
How does HTA for orphan drugs differ across Europe?
George Underwood
England, Europe, France, Germany, HTA, NICE, orphan drugs, Rare diseases, Scotland, SMC, UK
0 Comment
England is risking its own opioid epidemic, says PHE
Phil Taylor
addiction, England, NHS England, opioid crisis, opioid epidemic
0 Comment
Deep Dive/ Digital/ Market Access
NHS England gets commercial
mike.hammerton@pharmaphorum.com
Clinical Commissioning Groups, Deep Dive: Access and Commercialisation, England, medicines, NHS
0 Comment
Market Access/ Views & Analysis/ Views and analysis
The shadow of Brexit on speed of access
Leela Barham
Brexit, England, HTA, NICE, Non-submissions, Scotland, SMC
0 Comment
Oncology/ Partner Content/ Partner content/ Press releases
The new CDF – Navigating Cancer Drug Access in England
Adam Jeffery
access, cancer, CDF, England, ICAS, IMS Health, pharma
0 Comment
Articles/ Audio/ Debates/ Debates/ Debates & Insight/ Debates & Insight/ Market Access/ Patients/ Pharma Market Access/ Webinars/ Webinars On demand
Available on-demand: The Price is Right? – Delivering UK access for niche patient populations
Paul Tunnah
budget, cancer, CF Trust, debate, drug, England, fund, IMS Health, insight, market access, NHS, orphan, Qualie, rare disease, Shire, Tunnah, UK
0 Comment